Patent application number | Description | Published |
20110002928 | Uses of Mammalian Cytokine; Related Reagents - Provided are methods of treatment for inflammatory and autoimmune disorders of the metabolic system. Also provided are methods of diagnosis. | 01-06-2011 |
20110135597 | Uses of Mammalian Cytokine; Related Reagents - Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule. | 06-09-2011 |
20120156699 | Pathogenic TH17 Cells; related reagents and methods - Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders. | 06-21-2012 |
20120177647 | MDL-1 USES - The invention provides methods for treating bone resorption disorders with antagonists of MDL-1. | 07-12-2012 |
20130071380 | MODULATION OF PILR TO TREAT IMMUNE DISORDERS - The present invention provides methods of using PILRα agonists, or PILRβ antagonists, to treat immune disorders, such as autoimmune and inflammatory disorders, including CNS, joint and gut inflammation. | 03-21-2013 |
20130287775 | COMBINATION THERAPY FOR TREATMENT OF IMMUNE DISORDERS - Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders. | 10-31-2013 |
20130323246 | USE OF MDL-1 ANTAGONISTS TO TREAT SPONDYLARTHROPATHY - The invention provides methods for treating spondylarthropathy with antagonists of MDL-1 alone or in combination with IL-23 antagonists. | 12-05-2013 |
20140234301 | Modulation of PILR to Treat Immune Disorders - The present invention provides methods of using PILRα agonists, or PILRβ antagonists, to treat immune disorders, such as autoimmune and inflammatory disorders, including CNS, joint and gut inflammation. | 08-21-2014 |